BioPharma Resources

Drug Trial Radar · NCT07318688

Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated Pain

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension

Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Mar 1, 2028

Study completion Sep 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 49 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 3 study to evaluate the efficacy and safety of HMI-115 in women with moderate to severe endometriosis-associated pain over a 24-week treatment period and a 28-week extension

Conditions

  • Endometriosis

Interventions

  • HMI-115Drug

    HMI-115 is human monoclonal antibody (120mg/vail)

  • PlaceboDrug

    Placebo (0mg/vail)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline (CFB) in dysmenorrhea (DYS) measured by Numeric Rating Scale (NRS) at Week 12Time frame: week 12
  2. CFB in non-menstrual pelvic pain (NMPP) measured by NRS at Week 12Time frame: week 12

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Nanjing Women and children's healthcare hospital

    Nanning, Jiangsu, China · Not yet recruiting

  • Second Affiliated Hospital of Soochow University

    Suzhu, Jiangsu, China · Recruiting

  • The International Peace Maternity and Child Health Hospital of the China Welfare Institute

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.